13.01M shares intraday: ALDEI.PA Deinove SA (EURONEXT) shows high activity

Today intraday ALDEI.PA stock is among the most active names on EURONEXT, exchanging 13,014,939 shares as traders respond to microcap volatility. The share price sits at €0.03 with a day range between €0.02 and €0.03. Volume is more than twice the average, at a relative volume of 2.17, underlining short-term liquidity and speculative flows for Deinove SA in Europe. We break down what the activity means for investors, the company’s fundamentals and a model-based short-term outlook.

Intraday snapshot: ALDEI.PA stock performance

ALDEI.PA stock is trading at €0.0265 on EURONEXT with today’s high at €0.03 and low at €0.02. Volume hit 13,014,939 shares versus an average of 5,992,347, signalling unusually high intraday interest. The market cap is €1,134,989.00, keeping Deinove SA firmly in the microcap bracket and exposing it to sharp price swings.

Why the high volume matters for ALDEI.PA stock

High intraday volume can tighten spreads and allow larger orders to fill, which is relevant for a thinly capitalised biotech like Deinove SA. Heavy trading today suggests short-term traders or news-driven repositioning rather than renewed long-term conviction. Increased liquidity helps price discovery but raises volatility risk for buy-and-hold investors.

Financial health and valuation for ALDEI.PA stock

Deinove SA is in the Biotechnology industry within Healthcare, with EPS at -0.24 and a negative PE. Price to Sales is 3.09 and EV/Sales is 9.85, reflecting limited revenue and high enterprise value relative to sales. The company reports cash per share of 0.13 and a current ratio of 1.36, indicating short-term coverage but ongoing cash burn shown by negative operating cash flow per share of -0.21.

Technical levels and trading signals for ALDEI.PA stock

Short-term averages show a 50‑day price at €0.02 and the 200‑day at €0.11, highlighting a steep downtrend over the long term. Today’s intraday high of €0.03 sits above the 50‑day average, suggesting temporary buying pressure. Traders should watch support near the year low €0.01 and resistance near the year high of €0.44 for extreme reversal points.

Meyka AI grade and model forecast for ALDEI.PA stock

Meyka AI rates ALDEI.PA with a score out of 100: 64.99 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a near-term reference price of €0.05, compared with the current price of EUR 0.0265, implying an upside of 88.68% under the model assumptions. Forecasts are model-based projections and not guarantees.

Risks and opportunities for ALDEI.PA stock

Key opportunities include progress in antibiotic candidate DNV3837 and demand for biotech-derived cosmetic ingredients. Partnerships with bioMérieux and Institut Pasteur support R&D credibility. Key risks are ongoing negative earnings, tight free cash flow, and microcap liquidity swings that can amplify downside. Investors should weigh clinical progress timelines against cash runway and dilution risk.

Final Thoughts

ALDEI.PA stock is trading as a high‑volume microcap on EURONEXT today, with 13,014,939 shares changing hands and a current quote of €0.0265. The heavy intraday activity improves execution but increases volatility for retail and institutional traders. Fundamentals show negative EPS (-0.24) and negative operating cash flow per share (-0.21), while price metrics such as P/S (3.09) and EV/Sales (9.85) reflect a valuation premium versus tracked revenue. Meyka AI’s model projects a short-term reference price of €0.05, implying roughly 88.68% upside versus EUR 0.0265 today; this projection assumes successful R&D progress and no near-term dilution. Meyka AI, an AI-powered market analysis platform, flags ALDEI.PA as a speculative HOLD based on sector comparison, key metrics and limited liquidity. For active traders the stock offers intraday opportunity; for longer-term investors the key drivers will be clinical updates, cash runway, and partner milestones. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.